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Abstract
Background: Microarrays provide a means to simultaneously examine the gene expression of the
entire transcriptome in a single sample. Many studies have highlighted the need for novel software
and statistical approaches to assess the measured gene expression. Less attention has been
directed toward whether genes considered undetectable by microarray can be detected by other
strategies or whether these genes can provide accurate gene expression determinations. In the
kidney this is a concern for genes such as cytokines which dramatically influence the immune
response but are often considered low abundance genes produced by a small number of cells.
Results: Using both publicly available and our own microarray datasets we analyzed the detection
p-value and detection call values for 81 human kidney samples run on the U133A or U133Plus2.0
Affymetrix microarrays (Affymetrix, Santa Clara, CA). For the cytokine genes, the frequency of
detection in each sample group (normal, transplant and renal cell carcinoma) was examined and
revealed that a majority of cytokine related genes are not detectable in human kidney by
microarray. Using a subset of 29 Mayo transplant samples, a group of seven transplant-related
cytokines and eight non-cytokine genes were evaluated by real-time PCR (rt-PCR). For these 15
genes we compared the impact of decreasing microarray detection frequency with the changes in
gene expression observed by both microarray and rt-PCR. We found that as microarray detection
frequency decreased the correlation between microarray and rt-PCR data also decreased.
Conclusion: We conclude that, when analyzing microarray data from human kidney samples,
genes generally expressed at low abundance (i.e. cytokines) should be evaluated with more
sensitive approaches such as rt-PCR. In addition, our data suggest that the use of detection
frequency cutoffs for inclusion or exclusion of microarray data may be appropriate when comparing
microarray and rt-PCR gene expression data and p-value calculations.
Background
The recent completion of the human genome project,
improvements in gene level annotation and microarray
technology have led to a rapid increase in the number of
whole genome microarray based studies for researchers
interested in understanding the underlying etiology of
various human conditions. However, there remain several
significant questions to answer with regard to microarray
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data acquisition and analyses, including the accurate
determination of signal intensity, development of opti-
mal analytical strategies and detection limit thresholds.
The most common oligonucleotide microarray platform
is made by Affymetrix Inc. and uses 25-mer probes to tar-
get gene sequences. Approximately 22 different probes,
equally divided between paired perfect match (PM) and
mismatch (MM) probes, make up a probeset which is
designed to target a specific gene. Fluorescent data from
each PM-MM pair is analyzed by the Affymetrix MAS 5.0
software and a single value for signal intensity, detection
p-value and detection call are generated for each probeset.
To determine the best method for analyzing the data, mul-
tiple software programs and statistical approaches have
been developed [1-6]. However, there continues to be
much debate regarding the inclusion of both PM and MM
probe signal intensities to provide the most accurate
measures of expression [7].
Additional interpretation of Affymetrix microarray data
frequently includes filtering the data on the basis of the
calculated detection p-value from which a detection call
of present, marginal or absent is made for each probeset.
Often this information is incorporated into downstream
analysis strategies by calculating the percent present (%P)
or detection frequency for a probeset based on all of the
samples in a study and omitting those probesets that fail
to reach the threshold. A recent study explored the effect
of filtering using a detection frequency cutoff and sug-
gested that filtering ≥ 50% %P may improve downstream
analysis [8]. However, typically only 30–40% of probesets
are considered detectable in any human tissue sample [9].
Therefore, the decision to include a detection frequency
cutoff will dramatically alter the number of probesets
used in downstream analysis.
It is important to note that the use of a detection fre-
quency filter presumes that genes which are considered
undetectable by the microarray are not actually present in
the sample. However, given the lack of sensitivity of
microarrays, transcripts of low abundance within a sam-
ple may not be detected [10]. One such family of genes are
the cytokines which may only be expressed by a small
fraction of the cells in human organs, such as the kidney,
or by a small number of infiltrating immune cells. Inter-
estingly, several members of the cytokine gene family
have been found significantly altered in samples of
human renal cell carcinoma (RCC) and kidney transplant
rejection [11-15]. In general, these associations have been
made using real-time PCR (rt-PCR) and not microarray.
To date no report has assessed the detectability of
cytokines with microarrays in human kidney under a vari-
ety of physiological conditions.
In this study we used a meta-analysis of publicly available
Affymetrix datasets to explore the detection frequency of
cytokine genes in the human kidney. We then selected a
subset of genes with high and low detection frequencies
and performed follow-up rt-PCR on a group of kidney
transplant samples. Finally, we performed a comparison
of gene expression changes observed by microarray and rt-
PCR to assess the accuracy of data obtained from high and
low detection frequency genes.
Results
Cytokine detection frequency in kidney
To assess the frequency with which cytokine genes are
identified as present or absent in human kidney we per-
formed a meta-analysis of publicly available (GEO)
Affymetrix microarray datasets related to human kidney
tissue. Data from the human U133A and U133Plus2.0
was selected as the sequence used for each probeset is
identical on each chip, with only the feature size and array
density being different. In addition we used data from 30
human kidney samples from our group. In total there
were 81 samples for which both Affymetrix derived detec-
tion p-values and detection calls had been made. For sim-
plification the samples were categorized into one of three
groups: normal kidneys (n = 15), transplanted kidneys (n
= 36) and RCC (n = 30). The thresholds for determining
detection calls, the default set by Affymetrix, were the
same for all samples.
According to the 4-16-06 Affymetrix annotation file for
the U133Plus2.0, there are 393 probesets identified as
being related to the "cytokine activity" Gene Ontology
classifier (GO:0005125), including many chemokine,
interleukin and interferon genes. We also included 5
probesets for the pro-inflammatory genes TGF-β1  and
FoxP3 which were previously associated with post kidney
transplant outcomes using rt-PCR [15,16]. Of the 398
total probesets, 244 (61.3%) had a detection frequency
less than 25%.
Table 1 shows a subset of the cytokine probesets, selected
primarily because they are designed to detect specific
interleukin or interferon genes. The name of the gene and
detection rate for all of the samples is provided as well as
the breakdown of the detection frequency in the various
types of samples. Importantly, using the gene name as an
identifier, it is clear that multiple probesets are present for
many genes but that these replicate probesets may not
always generate similar detection rates. For example, the
Interleukin 1 alpha gene has two probesets, one with an
overall detection rate of 63% while the other is just 1%. It
is unclear what the cause of such variation is but sequence
variants or poor probe design seem like plausible explana-
tions.BMC Genomics 2007, 8:88 http://www.biomedcentral.com/1471-2164/8/88
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Detection by rt-PCR versus microarray
Using 29 of the 30 human Mayo kidney transplant sam-
ples, we compared the detection frequency of cytokines
for both microarray and rt-PCR. We selected a small group
of cytokines that had been previously described using rt-
PCR to be associated with various clinical post-transplant
events but were represented by only one probeset (Table
2). We also looked for genes that had multiple undetecta-
ble probesets from the meta-analysis (TGFβ1 and FoxP3).
Finally, we included the IFNγ-receptor 1 (IFNγ-R1) gene to
serve as a positive control. There are three probesets for
this gene on the U133Plus2.0, all of which were detected
in 100% of human kidney samples.
To rule out incompatible probe sequence design issues we
performed a BLAST search of the Affymetrix consensus
sequence for each probeset. We found that, although there
are three probesets attributed to the FoxP3 gene on the
microarray, only one of the probesets has 100% homol-
ogy to the FoxP3 Reference Sequence number (NCBI:
NM_014009). The other two probesets bind to the JM2
sequence (NCBI: AJ005891) and do not share 100%
homology to the same FoxP3 sequence. A similar probe
design issue applies to one of the three IFNγ-R1 gene
probesets which actually binds to the intron region of the
DNA sequence for the gene and is therefore unsuitable for
mRNA analysis. This finding has been corroborated else-
where [17].
Once the probeset sequence was confirmed we performed
a comparison of the detection sensitivity between the two
platforms using separate aliquots of RNA from each sam-
ple. Seventy ng of total RNA was used for microarray
processing whereas each rt-PCR reaction used the equiva-
lent of 10 ng total RNA (1 μg RNA aliquot was cDNA
amplified and diluted 1:100). For the genes TNFα, IFNγ,
IL-10, TGF-β1 and FoxP3, none of the Mayo transplant
samples were detectable using the microarray (detection
p-values ranged from 0.562 to 0.9536) whereas using rt-
PCR all of these genes were detectable for all samples
tested. Likewise IL-6, selected because it was detectable in
70% of the microarray samples, and the positive control,
IFNγ-R1, were detectable by rt-PCR for all samples. In
addition, although a relative standard curve was
employed to monitor detection by rt-PCR, we did record
the minimum and maximum Ct for each gene target
(Table 2). There does not appear to be a strong correlation
between the microarray detection p-value and Ct value.
For example, TGF-β1 had one of the highest detection p-
values and one of the lowest Max Ct values.
Table 1: Microarray detection frequencies for various cytokines in human kidney samples.
Probe Set ID Gene Name Total samplesa %P ALL %P Normal (n = 15) %P Transplant (n = 36) %P Cancer (n = 30)
1 224211_at Forkhead box P3 (FoxP3) 60 0% 0% 0%
2 221333_at Forkhead box P3 (FoxP3) 81 0% 0% 0% 0%
3 221334_s_at Forkhead box P3 (FoxP3) 81 7% 0% 0% 20%
4 202727_s_at Interferon gamma receptor 1 (IFNγ-R1) 81 100% 100% 100% 100%
5 242903_at Interferon gamma receptor 1 (IFNγ-R1) 60 100% 100% 100%
6 211676_s_at Interferon gamma receptor 1 (IFNγ-R1) 81 99% 100% 97% 100%
7 201642_at Interferon gamma receptor 2 81 91% 80% 89% 100%
8 210354_at Interferon, gamma (IFNγ) 81 10% 0% 3% 23%
9 208200_at Interleukin 1, alpha 81 63% 33% 53% 90%
10 210118_s_at Interleukin 1, alpha 81 1% 0% 0% 3%
11 39402_at Interleukin 1, beta 81 38% 33% 47% 30%
12 205067_at Interleukin 1, beta 81 6% 20% 3% 3%
13 207849_at Interleukin 2 81 4% 7% 6% 0%
14 207906_at Interleukin 3 81 0% 0% 0% 0%
15 207539_s_at Interleukin 4 81 0% 0% 0% 0%
16 207538_at Interleukin 4 81 0% 0% 0% 0%
17 207952_at Interleukin 5 81 0% 0% 0% 0%
18 205207_at Interleukin 6 (IL-6) 81 60% 73% 64% 50%
19 206693_at Interleukin 7 81 64% 40% 64% 77%
20 241808_at Interleukin 7 60 72% 42% 100%
21 202859_x_at Interleukin 8 81 65% 53% 50% 90%
22 211506_s_at Interleukin 8 81 14% 20% 0% 27%
23 208193_at Interleukin 9 81 1% 0% 0% 3%
24 207433_at Interleukin 10 (IL-10) 81 4% 7% 0% 7%
25 206924_at Interleukin 11 81 0% 0% 0% 0%
26 206926_s_at Interleukin 11 81 0% 0% 0% 0%
27 207844_at Interleukin 13 81 0% 0% 0% 0%
28 203085_s_at Transforming growth factor, beta 1 (TGF-β1) 81 49% 67% 0% 100%
29 203084_at Transforming growth factor, beta 1 (TGF-β1)8 1 1 % 0 % 0 % 3 %
30 207113_s_at Tumor necrosis factor, alpha (TNF-α) 81 9% 0% 0% 23%
a For each probeset the total number of samples was either 60 or 81. The U133A does not contain all of the probesets from the U133Plus2.0. 
U133A data was used for 15 "Normal" and 6 "Transplant" samples.BMC Genomics 2007, 8:88 http://www.biomedcentral.com/1471-2164/8/88
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Further evidence for increased detection sensitivity of rt-
PCR over microarrays is provided by data from an addi-
tional eight non-cytokine genes. Using rt-PCR all samples
were considered detectable by rt-PCR even though the
detection frequencies ranged from 42–100%.
Gene expression differences
Using the same transplant samples as above we compared
the impact of decreased microarray detection frequencies
with the changes in gene expression observed by both
microarray and rt-PCR. Changes in gene expression were
examined using two distinct patient groups. The first
group contained patients that had normal renal pathology
at both the time of transplant and subsequent 12 month
protocol biopsy (TxNormal [0–12]). The second patient
group had normal pathology at the time of transplant but
showed evidence of fibrosis on the 12 month protocol
biopsy (TxFibrosis [0–12]). The microarray data from
both patient groups was analyzed for the changes in gene
expression that occurred from the time of transplant to 12
months. A comparison of the microarray and rt-PCR gene
expression data was performed using the same 15 genes
described above (Table 3). All genes were detected by rt-
PCR in each sample, whereas by microarray the samples
showed a continuum of detection frequency. As can be
seen in Table 3, the five cytokine genes considered unde-
tectable by microarray show no correlation with the rt-
PCR data, both in terms of the determination of up/down-
regulation and significance. In stark contrast, the high
detection frequency genes showed an excellent correlation
between microarray and rt-PCR data. Nineteen of the
twenty comparisons, including instances of up/down-reg-
ulation, correlate. The only instance where correlation did
not occur was when the detection frequency was <50%.
Discussion
Using a meta-analysis of publicly available kidney micro-
array datasets we were able to show that the Affymetrix
platform fails to detect a number of human cytokine
genes. For a subset of these samples we were able to show
that cytokine genes considered undetectable by microar-
ray were detectable using rt-PCR. This is a significant find-
ing as cytokines are known to be important peptides that
regulate innate host defenses and the immune system
[18]. In fact, it is currently believed that the underlying eti-
ology of various human conditions such as cancers or
transplant rejections involve the expression of multiple
cytokines.
The oncogenesis of RCC, which accounts for approxi-
mately 80% of all kidney tumors in adults, has been
hypothesized to involve modulated cancer cell expression
of inflammatory cytokines [11,19,20]. Indeed, multiple
cytokines are currently used as immunotherapies to treat
this disease [21]. In addition, various reports have linked
either the detection of or increased presence of various
cytokine mRNA species with disease progression, typically
through the use of rt-PCR [for review see [22]]. For exam-
ple, IFN-γ, interleukins 2, 6, 8 and 10 and TNFα have all
been identified as detectable or significantly altered in
human RCC tumors [11-13,23]. Our meta-analysis
showed that in 30 RCC samples, only interleukin 8 had a
Table 2: Cytokine genes examined by microarray and rt-PCR in Mayo Clinic kidney transplant specimens.
Microarray detection rt-PCR detection
Gene Name Probe Set ID BLAST of 
Consensus Probe 
Sequence OK?
%P of Mayo 
samples (n = 30)
Min 
Detection p-
value
Max 
Detection p-
value
%Detected in 
Mayo samples 
(n = 29)
Min Ct Max Ct
1 TNF-α 207113_s_at Yes 0.0% 0.0806 0.3989 100% 30.03 36.48
2I F N γ 210354_at Yes 0.0% 0.0562 0.5676 100% 32.97 41.78
3 IL-6 205207_at Yes 70.0% 0.0007 0.1116 100% 30.83 39.89
4 IL-10 207433_at Yes 0.0% 0.1116 0.6963 100% 32.82 37.16
5T G F - β 1
203085_s_at Yes 0.0% 0.1497 0.9324 100% 26.55 32.54
203084_at Yes 0.0% 0.1497 0.6338 100% 26.55 32.54
6F o x P 3
224211_at Yes 0.0% 0.2742 0.8286 100% 30.87 37.22
221333_at NOa 0.0% 0.6655 0.9539 - - -
221334_s_at NOa 0.0% 0.0806 0.6655 - - -
7I F N γ-R1
202727_s_at Yes 100.0% 0.0002 0.0020 100% 28.53 33.95
242903_at NOb 100.0% 0.0002 0.0376 - - -
211676_s_at Yes 96.7% 0.0007 0.0676 100% 28.53 33.95
a Contains probesets for the FoxP3 gene which overlap with the JM2 gene.
b Contains probesets for the IFNγ-Receptor 1 gene that specifically bind the DNA sequence of the gene.BMC Genomics 2007, 8:88 http://www.biomedcentral.com/1471-2164/8/88
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probeset that was detected in more than half of the sam-
ples, with interleukins 2 and 10 considered detectable in
less than 10% of the samples.
In human kidney transplantation several reports have also
linked the gene expression of various cytokines with trans-
plant events such as acute and chronic rejection [14,15].
Table 3: Comparisons of changes in gene expression determined by microarray and rt-PCR in Mayo Clinic kidney transplant 
specimens.
RT-PCR Microarray
Transcript Analysis Fold change p-valuea Fold change p-value %P Acceptable correlationb
A. Undetectable by microarray
TNFα
TxNormal (0–12) 1.62 0.288 -1.05 0.051 0% No
TxFibrosis (0–12) 2.05 0.061 -1.01 0.728 0% No
IFNγ
TxNormal (0–12) 2.72 0.172 -1.04 0.152 0% No
TxFibrosis (0–12) 3.11 0.028 1.02 0.537 0% No
IL-10
TxNormal (0–12) 1.54 0.271 -1.05 0.058 0% No
TxFibrosis (0–12) 3.02 0.000 -1.05 0.134 0% No
TGFβ1
TxNormal (0–12) 2.53 0.003 -1.11 0.012 0% No
TxFibrosis (0–12) 2.93 0.000 -1.09 0.002 0% No
Fox-P3
TxNormal (0–12) 2.56 0.030 -1.07 0.029 0% No
TxFibrosis (0–12) 2.33 0.000 -1.13 0.001 0% No
B. Detectable by microarray
GRZMA
TxNormal (0–12) 7.25 0.021 1.32 0.072 42% No
TxFibrosis (0–12) 9.21 0.000 2.06 0.000 50% Yes
IL-6
TxNormal (0–12) -12.50 0.029 -1.26 0.008 79% Yes
TxFibrosis (0–12) -7.69 0.005 -1.23 0.000 63% Yes
FN1
TxNormal (0–12) 2.84 0.001 2.78 0.020 93% Yes
TxFibrosis (0–12) 2.50 0.002 2.01 0.001 94% Yes
IFNγ-R1
TxNormal (0–12) 1.45 0.072 1.35 0.061 100% Yes
TxFibrosis (0–12) 1.63 0.001 1.37 0.008 100% Yes
IER3
TxNormal (0–12) -2.80 0.016 -2.54 0.000 100% Yes
TxFibrosis (0–12) -2.24 0.005 -1.70 0.000 100% Yes
STAT2
TxNormal (0–12) 1.72 0.015 1.40 0.005 100% Yes
TxFibrosis (0–12) 1.88 0.016 1.43 0.001 100% Yes
COL1A1
TxNormal (0–12) 8.89 0.037 5.82 0.005 100% Yes
TxFibrosis (0–12) 8.76 0.001 5.34 0.000 100% Yes
STAT1
TxNormal (0–12) 2.06 0.001 1.89 0.000 100% Yes
TxFibrosis (0–12) 2.80 0.002 2.19 0.000 100% Yes
VCAM1
TxNormal (0–12) 1.42 0.168 1.34 0.254 100% Yes
TxFibrosis (0–12) 2.43 0.000 2.00 0.000 100% Yes
PSMB8
TxNormal (0–12) 1.78 0.019 1.40 0.041 100% Yes
TxFibrosis (0–12) 2.82 0.000 1.83 0.000 100% Yes
a Calculated by TTEST (equal variance, 2-tailed distribution).
b To be considered "acceptable" both the direction of change (up/down- regulation) and significance (p < 0.05 or p > 0.05) must be the same.BMC Genomics 2007, 8:88 http://www.biomedcentral.com/1471-2164/8/88
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Similar to RCC, these links were made using single gene
strategies such as rt-PCR, yet the majority of these
cytokines were not observed in any of the transplant sam-
ples via microarray. For example, TGF-β1 has been shown
in multiple studies to be linked with chronic rejection but
was considered absent in all 36 transplant microarray
samples.
The lack of detection of relevant cytokine genes could be
related to several issues including improper gene annota-
tion at both the probeset and probe level. Gene annota-
tion is the assignment of gene level information based on
the probeset sequences, such as the name and symbol of
the gene being interrogated and its general function. As
knowledge of a probeset sequence increases it is possible
that a probeset will be designated a different gene name.
Perez-Iratxeta et al. explored this idea using Affymetrix
murine microarrays and showed that as many as 30%
(13699/45000) of the probesets were reassigned to a dif-
ferent gene at least once over a two year period [24]. We
examined the four quarterly U133Plus2.0 Affymetrix
annotation files from 2005 and found the amount of gene
assignment changes between probesets ranged between
7–15% each quarter (Data not shown). However, none of
the cytokine probesets subjected to rt-PCR for this study
had a change in gene assignment during that time.
Individual probe sequences can also impact gene annota-
tion. For some probesets not all probes interrogate the
mRNA sequence for a single gene. We found this was the
case for three of the fourteen cytokine probesets manually
examined by BLAST. Two of the probesets have probes
that appear to bind a different gene and one probeset has
probes that bind to the intron region of the target gene.
Recently Harbig et al. used the BLAST program to interro-
gate the sequence of all the U133Plus2.0 probes against
the human genome [17]. Their analyses showed that
approximately 37% of the probesets on the U133Plus2.0
should be assigned to a different gene. If we compare the
re-assigned data to our list of cytokine probesets we find
that approximately 75% (293/398) would have the same
gene assignment. However, the percentage of probesets
with a detection frequency less than 25% would not
change.
Another explanation for the lack of detection could be
that microarrays are generally considered less sensitive
overall than rt-PCR platforms. This decreased sensitivity
could be attributed to several factors including the varia-
tion in platform chemistries or probe sequence lengths
and designs. However, few groups have compared the
detection and correlation of microarrays to rt-PCR in a
systematic manner in human samples [25-27]. Wang et al
generated rt-PCR data on 1,375 human genes and com-
pared this data to that generated by Applied Biosystems
and Agilent microarrays. Using the rt-PCR data as the
"ground truth", they found that microarrays did not detect
between 24 and 29% of the genes detected by rt-PCR [26].
These findings compliment our data as wewere able to
detect several cytokine genes by rt-PCR that we did not
detect using microarray even though the amount of input
RNA was higher in the microarray samples. This suggests
that microarrays may yield a significant number of false
negative detection calls when compared to rt-PCR. In con-
trast, for probesets considered detected in all samples we
have consistently been able to use rt-PCR to detect the
gene, suggesting the false positive rate for the detection of
moderately expressed genes is relatively low.
Although taking into account the lack of detection of
genes is important in microarray analysis, it is equally
important to ensure that only the most accurate measures
of gene expression are being examined. Typically this is
done by removing the probesets exhibiting signal consid-
ered below the threshold of detection. One approach to
eliminate these probesets is to use a detection frequency
filter and then proceed with statistical analysis on the
remaining probesets. Despite its significance, there are few
reports that directly discuss what the detection frequency
should be or its effect on data accuracy. However, a recent
paper by McClintick et al. concluded that restrictive filter-
ing, such as a ≥ 50% %P, greatly improves the reproduci-
bility and the false discovery rate [8]. Our data both
corroborates and extends these findings by showing that
observed changes in gene expression by microarray corre-
late very well with rt-PCR when the probeset has a detec-
tion frequency of >50% for the samples under
consideration. Conversely, when a probeset is not consid-
ered detectable in the majority of samples the correlation
between rt-PCR and microarray data is quite poor. Similar
to our findings, Etienne et al. also reported finding a lower
correlation between rt-PCR and raw Affymetrix signal data
as the percentage of absent calls increased [28]. The fact
that multiple reports have now shown an important cor-
relation between the detection frequency and rt-PCR sug-
gests that this is an important issue to consider when
performing microarray analysis.
Conclusion
Our meta-analysis of publicly available microarray data-
sets revealed that microarrays failed to detect multiple
cytokine genes that have been linked to various human
kidney conditions. This lack of detection may be related to
incorrect gene annotation or limited assay sensitivity. For
a subset of genes, a comparison between detection fre-
quencies using microarrays and rt-PCR platforms showed
that rt-PCR is the more sensitive platform. The detection
frequency also had an effect on measured changes in gene
expression. For genes considered detectable in the major-
ity of microarray samples, the changes in gene expressionBMC Genomics 2007, 8:88 http://www.biomedcentral.com/1471-2164/8/88
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observed by microarray and rt-PCR had excellent correla-
tion. No correlation was observed between rt-PCR and
microarray when the detection frequency dropped below
50%. Therefore, in the human kidney we would recom-
mend using rt-PCR to detect and assess changes in gene
expression among genes of low abundance, such as
cytokines, rather than microarrays.
Methods
Affymetrix microarray overview
For human samples Affymetrix offers two popular high
density microarrays: the U133A and the whole genome
U133Plus2.0 microarrays. The U133A contains approxi-
mately 22,000 probesets while the U133Plus2.0 has even
smaller feature size and contains 54,675 probesets repre-
senting approximately 24,000 novel gene titles or Uni-
Gene IDs. The majority of probesets contain a total of 22
different 25-mer probes, equally divided between paired
perfect match (PM) and mismatch (MM) probes. Each
MM probe contains a single base pair difference from its
PM counterpart, a single base pair change at the center
nucleotide, and its fluorescence is intended to represent
background non-specific hybridization. Fluorescent data
from each PM-MM pair is then analyzed by the Affymetrix
MAS 5.0 software and a single value for signal intensity,
detection p-value and detection call (among other varia-
bles) are generated for each probeset. For our study, the
MAS 5.0 default parameters were retained. For a complete
description of the MAS 5.0 algorithms and statistical tests
please refer to the Affymetrix manuals [29]. Importantly,
for each microarray, Affymetrix releases a new annotation
file that is updated each quarter and contains a large
amount of information, including the gene name, Uni-
Gene ID and gene ontology associated with each probeset
and probeset sequence [30].
Public microarray datasets
Microarray datasets were obtained from the publicly avail-
able Gene Expression Omnibus (GEO) website [31]. GEO
Datasets were queried, filtered and selected on the basis of
human kidney and Affymetrix platform data. In addition,
to be included in the study the following fields were
required to be reported: probeset ID, expression value,
detection call and detection p-value. A total of three data
series fulfilled these requirements: GSE2004, GSE3297
and GSE2109. All data was generated using MAS 5.0
(Affymetrix, Inc., Santa Clara, CA) with the same detec-
tion call cutoffs used to determine presence or absence for
each probeset.
Internal microarray datasets
An additional 30 samples were obtained from kidney
transplant patients biopsied using a protocol approved by
the Institutional Review Board of the Mayo Foundation
and Clinic. Total RNA was extracted from each biopsy in
a RNA-only area using a modified and previously opti-
mized (for this type/size of sample) extraction method
using TRIzol® Reagent (Invitrogen Corp, Carlsbad, CA)
followed by clean-up with RNeasy Mini Kit® (Qiagen Inc.,
Valencia, CA) [32]. RNA integrity was assessed to ensure
RNA quality and the samples were sent to the Mayo
Advanced Genomics Technology Center (AGTC) which
processes ~1,000 GeneChips each year. The AGTC proc-
essed 70 ng of total RNA for all samples using the two-
cycle target labeling, hybridization and scanning proce-
dure described in detail in the Affymetrix GeneChip®
Expression Analysis Manual (Affymetrix Inc., Santa Clara,
CA). The .cel files from this study can be downloaded
from the GEO website: GSE7392.
Changes in gene expression
Using the Mayo microarray data, two groups of transplant
patients were analyzed to assess the changes in gene
expression observed by microarray. The first patient group
(n = 7) had normal pathology both at the time of trans-
plant (baseline) and at 12 months post transplant
(TxNormal [0–12]). The second group of patients (n = 8)
had normal pathology at the time of transplant and
showed evidence of fibrosis at 12 months post transplant
(TxFibrosis [0–12]). For each patient group differential
gene expression (baseline to 12 months post transplant)
was assessed using a PM-only model, wherein only the
data from the PM probes was used to estimate the expres-
sion level of individual probesets. The PM data from each
chip was subjected to FASTLO, a previously described
non-linear method of normalization [6]. Significance for
each probeset in this case was determined using a general-
ized linear model with random effects for chip and treat-
ment, analogous to a t-test. P-values were not adjusted for
multiple comparisons.
rt-PCR
To confirm the presence or absence of specific cytokine
genes recorded by the microarray, a rt-PCR strategy was
employed. Using the Mayo Clinic General Clinical
Research Center we utilized rt-PCR to examine target
genes and a housekeeping gene (18S) for 29 of the Mayo
samples for which at least 1 μg of RNA was available for
cDNA synthesis. For each gene, assays containing pre-
designed primers and probes designed from the matching
Reference Sequence number provided by Affymetrix were
purchased from ABI (Applied Biosystems, Foster City,
CA). To generate the standard curves, we created a large
pool of human RNA that contained 90% human kidney
RNA and 10% mononuclear cell RNA. The mononuclear
cell RNA was included to ensure that cytokine mRNA
would be present in the control RNA pool. Several 1 μg
aliquots of control RNA were converted into cDNA and,
after testing to confirm equal efficiency, were batched
together. A 10-point standard curve was amplified in trip-BMC Genomics 2007, 8:88 http://www.biomedcentral.com/1471-2164/8/88
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licate along with a triplicate amplification of each sample
(10 ng/rxn). For each assay the top curve point was 36 ng
control cDNA followed by multiple 2.5-fold dilutions to
as low as 0.01 ng/rxn. While not all assays successfully
amplified the lowest points in the curve, no curve ampli-
fied less than 6 consecutive points. For example, all 10-
points amplified for TGF-β1, the top 8 amplified for IL-10
and the top 6 for IFNγ. For each assay we assessed the Ct
value for each triplicate standard curve point and found
that the majority had a %CV <1%. The highest %CV was
2.89%. For a particular gene to be considered detectable
in a given sample the Ct value for the sample reactions
needed to be above the lowest detected point on the cor-
responding standard curve. Cytokine gene selection was
based on the presence of the gene in one of three catego-
ries: a. Undetectable in all Mayo microarray samples: IFNγ
(ABI#: Hs99999041_m1), TNFα(Hs00174128_m1), IL-
10 (Hs00174086_m1), TGF-β1 (Hs00998133_m1) and
FoxP3 (Hs00203958_m1). b. Undetectable in some Mayo
microarray samples: IL-6 (Hs99999032_m1), c. Detecta-
ble in all Mayo microarray samples: IFNγ-R1
(Hs00988304_m1). Using a strategy similar to that noted
above 8 additional non-cytokine genes, the majority of
which were detected in all microarray samples, were
amplified to compare observed changes in gene expres-
sion. These genes were GRZMA (Hs00196206_m1), FN1
(Hs00277509_m1), IER3 (Hs00174674_m1), STAT2
(Hs00237139_m1), COL1A1 (Hs00164004_m1), STAT1
(Hs00234829_m1), VCAM1 (Hs00174239_m1) and
PSMB8 (Hs00188149_m1).
List of abbreviations
Advanced Genomics Technology Center (AGTC)
Gene Expression Omnibus (GEO)
Mismatch (MM)
Percent present (%P)
Perfect Match (PM)
Real-time PCR (rt-PCR)
Renal cell carcinoma (RCC)
Authors' contributions
WP was responsible for designing, analyzing, collating
and interpreting the data and drafting the paper. MS con-
tributed to the design of the study and read the manu-
script and provided comments. All authors read and
approved the final manuscript.
References
1. Li C, Wong WH: Model-based analysis of oligonucleotide
arrays: model validation, design issues and standard error
application.  Genome Biol 2001, 2:RESEARCH0032.
2. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ,
Scherf U, Speed TP: Exploration, normalization, and summa-
ries of high density oligonucleotide array probe level data.
Biostatistics 2003, 4:249-264.
3. Wu Z, Irizarry RA: Preprocessing of oligonucleotide array
data.  Nature Biotechnology 2004, 22:656-658.
4. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S,
Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W,
Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G,
Smith C, Smyth G, Tierney L, Yang JY, Zhang J: Bioconductor: open
software development for computational biology and bioin-
formatics.  Genome Biology 2004, 5:R80.1-16.
5. Ingenuity pathway analysis: Ingenuity Systems Inc   [https://
analysis.ingenuity.com/pa]
6. Ballman KV, Grill DE, Oberg AL, Therneau TM: Faster cyclic loess:
normalizing RNA arrays via linear models.  Bioinformatics 2004,
20:2778-2786.
7. Millenaar FF, Okyere J, May ST, van Zanten M, Voesenek LA, Peeters
AJ: How to decide? Different methods of calculating gene
expression from short oligonucleotide array data will give
different results.  BMC Bioinformatics 2006, 7:137.
8. McClintick JN, Edenberg HJ: Effects of filtering by present call on
analysis of microarray experiments.  BMC Bioinformatics 2006,
7:49.
9. Affymetrix technical note: Design and Performance of the
GeneChip®  Human Genome U133 Plus 2.0 and Human
Genome U133A 2.0 Arrays   [http://www.affymetrix.com/sup
port/technical/technotes/hgu133_p2_technote.pdf]
10. Oudes AJ, Roach JC, Walashek LS, Eichner LJ, True LD, Vessella RL,
Liu AY: Application of Affymetrix array and Massively Parallel
Signature Sequencing for identification of genes involved in
prostate cancer progression.  BMC Cancer 2005, 5:86.
11. Olive C, Cheung C, Nicol D, Falk MC: Expression of cytokine
mRNA transcripts in renal cell carcinoma.  Immunol Cell Biol
1998, 76:357-362.
12. Chudek J, Schullerus D, Wilhelm M, Kovacs G: Lack of interleukin
6 (IL-6) and transforming growth factor alpha (TGF-alpha)
expression in chromophobe renal cell carcinomas.  Br J Cancer
1998, 78:1162-1164.
13. Ueno S, Saito S, Wada T, Yamaguchi K, Satoh M, Arai Y, Miyagi T:
Plasma membrane-associated sialidase is up-regulated in
renal cell carcinoma and promotes interleukin-6-induced
apoptosis suppression and cell motility.  J Biol Chem 2006,
281:7756-7764.
14. Zegarska J, Paczek L, Pawlowska M, Podrzucki W, Rowinski W,
Malanowski P, Wszola M, Mroz A: Quantitative gene expression
of TGF-beta1, TNF-alpha, IL-1beta, and IL-6 in the renal
artery wall of chronically rejected human renal allografts.
Transplant Proc 2002, 34:3176-3179.
15. Hribova P, Kotsch K, Brabcova I, Vitko S, Volk HD, Lacha J:
Cytokines and chemokine gene expression in human kidney
transplantation.  Transplant Proc 2005, 37:760-763.
16. Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB,
Hartono C, Li B, Sharma VK, Seshan SV, Kapur S, Hancock WW,
Schwartz JE, Suthanthiran M: Messenger RNA for FOXP3 in the
urine of renal-allograft recipients.  N Engl J Med 2005,
353:2342-2351.
17. Harbig J, Sprinkle R, Enkemann SA: A sequence-based identifica-
tion of the genes detected by probesets on the Affymetrix
U133 plus 2.0 array.  Nucleic Acids Res 2005, 33:e31.
18. Thomson AW, Lotze MT, (editors): The Cytokine Handbook, New
York, Academic Press; 2003:638. 
19. Rogers CG, Tan MH, Teh BT: Gene expression profiling of renal
cell carcinoma and clinical implications.  Urology 2005,
65:231-237.
20. Oya M, Takayanagi A, Horiguchi A, Mizuno R, Ohtsubo M, Marumo
K, Shimizu N, Murai M: Increased nuclear factor-kappa B acti-
vation is related to the tumor development of renal cell car-
cinoma.  Carcinogenesis 2003, 24:377-384.
21. Hutson TE, Quinn DI: Cytokine therapy: a standard of care for
metastatic renal cell carcinoma?  Clin Genitourin Cancer 2005,
4:181-186. ReviewPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Genomics 2007, 8:88 http://www.biomedcentral.com/1471-2164/8/88
Page 9 of 9
(page number not for citation purposes)
22. Wong ML, Medrano JF: Real-time PCR for mRNA quantitation.
Biotechniques 2005, 39:75-85. Review
23. Gogusev J, Augusti M, Chretien Y, Droz D: Interleukin-6 and TNF
alpha production in human renal cell carcinoma.  Kidney Int
1993, 44:585-592.
24. Perez-Iratxeta C, Andrade MA: Inconsistencies over time in 5%
of NetAffx probe-to-gene annotations.  BMC Bioinformatics 2005,
6:183.
25. Canales RD, Luo Y, Willey JC, Austermiller B, Barbacioru CC, Boysen
C, Hunkapiller K, Jensen RV, Knight CR, Lee KY, Ma Y, Maqsodi B,
Papallo A, Peters EH, Poulter K, Ruppel PL, Samaha RR, Shi L, Yang
W, Zhang L, Goodsaid FM: Evaluation of DNA microarray
results with quantitative gene expression platforms.  Nature
Biotechnol 2006, 24:1115-1122.
26. Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, Blake J,
Chan F, Gonzalez C, Zhang L, Samaha RR: Large scale real-time
PCR validation on gene expression measurements from two
commercial long-oligonucleotide microarrays.  BMC Genomics
2006, 7:59.
27. Dallas PB, Gottardo NG, Firth MJ, Beesley AH, Hoffmann K, Terry
PA, Freitas JR, Boag JM, Cummings AJ, Kees UR: Gene expression
levels assessed by oligonucleotide microarray analysis and
quantitative real-time RT-PCR – how well do they correlate?
BMC Genomics 2005, 6:59.
28. Etienne W, Meyer MH, Peppers J, Meyer RA Jr: Comparison of
mRNA gene expression by RT-PCR and DNA microarray.
Biotechniques 2004, 36:618-626.
29. Affymetrix Technical Manuals   [http://www.affymetrix.com/sup
port/technical/manuals.affx]
30. Affymetrix Annotation files   [http://www.affymetrix.com/sup
port/technical/annotationfilesmain.affx]
31. Gene Expression Omnibus (GEO) website   [http://
www.ncbi.nlm.nih.gov/projects/geo/]
32. Park WD, Grande JP, Ninova D, Nath KA, Platt JL, Gloor JM, Stegall
MD:  Accommodation in ABO-incompatible kidney allo-
grafts, a novel mechanism of self-protection against anti-
body-mediated injury.  Am J Transplant 2003, 3:952-960.